Goldman Sachs Upgrades Boston Scientific (BSX) to Neutral
Get Alerts BSX Hot Sheet
Rating Summary:
33 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 11 | New: 43
Join SI Premium – FREE
Goldman Sachs upgraded Boston Scientific (NYSE: BSX) from Sell to Neutral with a price target of $13.00 (from $11.00).
Analyst David H. Roman said, "We upgrade shares of Boston Scientific (BSX) to Neutral from Sell, given what looks to be higher sustainable growth and more attractive valuation. Our thesis had been that organic top-line growth would be pressured given core end-market weakness and a slower ramp in pipeline products. We had been explicit that 3Q was a pivotal quarter for the stock and our views, as comps become harder, putting a greater onus on execution. The performance registered in 3Q and the forward outlook indicate a turn for the better. Since being added to the Americas Sell List (December 14, 2011), BSX is +140% vs. the S&P500 +59%. LTM, BSX is flat vs. the S&P500 +10%."
For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.
Shares of Boston Scientific closed at $12.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Upgrades Airbus SE (AIR:FP) (EADSY) to Outperform, 'positive shift in sentiment has room to run'
- Legrand SA (LR:FP) (LGRDY) PT Raised to EUR94 at Jefferies as 'EU volumes continued to improve in January'
- BofA Securities Starts Avis Budget Group (CAR) at Buy, 'Even on a Budget, CAR looks attractive'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT Change, UpgradesRelated Entities
Goldman Sachs, Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!